Arecor Therapeutics PLC (AIM:AREC)'s CEO, Sarah Howell gave Proactive London the rundown on its interim results, its raft of trials and lots of progress elsewhere.
Howell also spoke about the 'excellent clinical progress' being made in their proprietary insulins geared towards diabetes sufferers, and the importance of the ongoing trials for its AT247 insulin jab.
Results from the trial are due this half, while work to follow up on the success of the initial trial of another diabetes product, AT278, is ramping up with towards a study in Type 2 diabetes sufferers.
#Arecor Therapeutics #insulin #diabetes #AIM